PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32166319-0	2020	The integrase inhibitors dolutegravir and raltegravir exert pro-adipogenic and profibrotic effects and induce insulin resistance in human/simian adipose tissue and human adipocytes.	dolutegravir	25-37	insulin	Homo sapiens	110-117	
30541118-0	2019	Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients.	dolutegravir	129-141	insulin	Homo sapiens	15-22	
31971958-0	2020	HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.	dolutegravir	26-38	insulin	Homo sapiens	145-152	
31971958-14	2020	In USP18-silenced cells, basal insulin resistance was increased, but dolutegravir and atazanavir/r kept their effect on insulin sensitivity, indicating that USP18 was dispensable.	dolutegravir	69-81	insulin	Homo sapiens	120-127	
31971958-18	2020	Thus, in endothelial cells, dolutegravir and atazanavir/r oppositely affected pathways leading to inflammation, senescence and insulin resistance.	dolutegravir	28-40	insulin	Homo sapiens	127-134	
30541118-8	2019	CONCLUSIONS: In HIV-positive subjects on suppressive cART, the switch from a PI/r to raltegravir or dolutegravir led to a significant and comparable reduction in both HOMA index and serum leptin level, reflecting a similar and significant improvement in insulin sensitivity.	dolutegravir	100-112	insulin	Homo sapiens	254-261	
34555326-14	2021	INTERPRETATION: Clinicians and people with HIV should be aware of associations between weight gain and use of dolutegravir, tenofovir alafenamide, and raltegravir, particularly given the potential consequences of weight gain, such as insulin resistance, dyslipidaemia, and hypertension.	dolutegravir	110-122	insulin	Homo sapiens	234-241